This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2006 Apr 5;295(13):1514; author reply 1514-5.

doi: 10.1001/jama.295.13.1514-a.

Efficacy and safety of edifoligide

Nimesh D Desai, Stephen E Fremes

PMID: 16595752
DOI: 10.1001/jama.295.13.1514-a

Comment

Efficacy and safety of edifoligide

Nimesh D Desai et al. JAMA. 2006.

. 2006 Apr 5;295(13):1514; author reply 1514-5.

doi: 10.1001/jama.295.13.1514-a.

Authors

Nimesh D Desai, Stephen E Fremes

PMID: 16595752
DOI: 10.1001/jama.295.13.1514-a

No abstract available

PubMed Disclaimer

Comment on

Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.
Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT; PREVENT IV Investigators. Alexander JH, et al. JAMA. 2005 Nov 16;294(19):2446-54. doi: 10.1001/jama.294.19.2446. JAMA. 2005. PMID: 16287955 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information